Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2009
05/14/2009US20090124598 Pharmaceutical use of substituted amides
05/14/2009US20090124597 such as oxazoline spiro-dibenzosuberenone compounds; cardiovascular, metabolic, immune disorders
05/14/2009US20090124596 Chemical Compounds 637
05/14/2009US20090124595 Mapk/erk kinase inhibitors
05/14/2009US20090124594 Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases
05/14/2009US20090124593 Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their ExtraGenital Complications
05/14/2009US20090124592 Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity
05/14/2009US20090124591 Synthesis and Use of Cationic Steroids for Anti-Inflammatory Drug Therapy
05/14/2009US20090124590 Pharmaceutical composition
05/14/2009US20090124589 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickener; extended time high blood serum concentration; rapidly absorbed gel; treatment of male hypogonadism
05/14/2009US20090124588 Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
05/14/2009US20090124587 METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
05/14/2009US20090124586 Aqueous-based pharmaceutical composition
05/14/2009US20090124585 Novel Crystalline Pharmaceutical Product
05/14/2009US20090124584 Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
05/14/2009US20090124583 7-N-substituted phenyl tetracycline compounds
05/14/2009US20090124582 Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use
05/14/2009US20090124581 Novel phosphonic acid compounds as inhibitors of serine proteases
05/14/2009US20090124580 Autoimmune diseases; water solubility of prodrug can be tailored to improve bioavailability using substution at amine groups; inhibitors of degranulation of immune cells; inhibit/activate Fc receptor signaling cascades
05/14/2009US20090124579 Systems and Methods For Determination of Compounds for Stimulation or Inhibition of Neocalcification
05/14/2009US20090124578 administering 3-(4'-Morpholin-4-ylmethyl-biphenyl-4-ylmethyl)-1-oxa-3-aza-spiro[4.5]decan-2-one, for the treatment of schizophrenia
05/14/2009US20090124577 Intermediate Compounds for the Preparation of an Angiotensin II Receptor Antagonist
05/14/2009US20090124574 Carotenoid analogs and derivatives for the prevention of platelet aggregation
05/14/2009US20090124573 Immunomodulating compounds and related compositions and methods
05/14/2009US20090124572 Iron-containing nutritional supplement
05/14/2009US20090124571 Method for the synthesis of oligonucleotide derivatives
05/14/2009US20090124570 Methods and Compositions for Facilitating Tissue Repair and Diagnosing, Preventing, and Treating Fibrosis
05/14/2009US20090124569 Inhibition and treatment of prostate cancer metastasis
05/14/2009US20090124568 Use of stem cells to generate inner ear cells
05/14/2009US20090124567 Influenza Therapeutic
05/14/2009US20090124566 Methods and compositions for the treatment of erythrocyte diseases
05/14/2009US20090124565 comprising an oligonucleotide and cetalkonium chloride (CKC) also called Benzyl n-hexadecyl dimethylammonium chloride wherein the ratio of CKC to mers of the oligonucleotide is below 0.55; prevention, treatment or relief of eye, lung, and/or respiratory tract conditions
05/14/2009US20090124564 Compositions and methods for regulating apoptosis
05/14/2009US20090124563 Oral extended-release composition
05/14/2009US20090124562 Versipelostatin derivative, anti-cancer agent and processes for production of the derivative and agent
05/14/2009US20090124561 Dihydroxyphenyl compounds and glucoside compounds thereof
05/14/2009US20090124559 Soft Protease Inhibitors and Pro-Soft Forms Thereof
05/14/2009US20090124558 Compositions and methods for treating neural anoxia and spreading depression
05/14/2009US20090124554 Buccal, polar and non-polar spray or capsule containing drugs for treating pain
05/14/2009US20090124551 Methods of administering bone health compositions derived from milk
05/14/2009US20090124549 administering to a patient infected with mycobacterium tuberculosis, a therapeutically effective amount of an isolated polypeptide ( a polypeptide covalently linked to a carrier); protective immune response
05/14/2009US20090124540 Anti-adhesion composites and methods of use thereof
05/14/2009US20090124535 Viscous terpolymers as drug delivery platform
05/14/2009US20090124534 Trehalose Click Polymers for Delivery of Biologically Active Molecules
05/14/2009US20090124009 Antisense modulation of ptp1b expression
05/14/2009US20090123941 Method and kit for detecting the early onset of renal tubular cell injury
05/14/2009US20090123579 Method of promoting weight loss
05/14/2009US20090123577 Liquid concentrate for preserving cosmetics
05/14/2009US20090123573 Admixture of extracts of plants of the genus rosmarinus and carotenoids for treating cutaneous symptoms of aging
05/14/2009US20090123572 Method and Pharmaceutical Composition for Treating Psoriasis, Squamous Cell Carcinoma and/or Parakeratosis by Inhibiting Expression of Squamous Cell Carcinoma-Related Antigen
05/14/2009US20090123571 Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
05/14/2009US20090123568 Kit useful for treating tumors and lesions of the skin and the mucous membranes
05/14/2009US20090123567 1,2-Bis[(1,2)-benzisoselenazol-3(2H)-onyl]ethane; high anti-oxidative activity and low toxicity; in combination with other anticarcinogenic, anticoagulant, antiinflammatory agents ( cisplatin, adriamycin, taxol; aspirin; indometacin)
05/14/2009US20090123565 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
05/14/2009US20090123562 Pharmaceutical Formulations of Gallium Salts
05/14/2009US20090123557 Dietary supplement composition for blood lipid health
05/14/2009US20090123555 Stimulateable Polymer Particles Exhibiting Reactive Functions, Method for the Production and the Use Thereof
05/14/2009US20090123554 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
05/14/2009US20090123552 Spheroids prepared from an isolated active principle of vegetable origin and a solution of vegetable origin containing the active principle or a precursor thereof
05/14/2009US20090123550 Corticosteroid compositions
05/14/2009US20090123549 Pharmaceutical Compositions
05/14/2009US20090123546 Polymer-based, sustained release drug delivery system
05/14/2009US20090123545 Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof
05/14/2009US20090123543 Pharmaceutical compositions
05/14/2009US20090123542 oral administered powder mixture comprising a dissolved whey protein to increase release the bioactive carotenoid, polyphenol, vitamins, flavonoid, isoflavone, ceramide
05/14/2009US20090123541 Pharmaceutical Composition
05/14/2009US20090123539 Wet granulation using a water sequestering agent
05/14/2009US20090123538 Angiotensin II Receptor Antagonists
05/14/2009US20090123537 Oral dosage form of ceftriaxone and methods of use
05/14/2009US20090123536 Oral Pharmaceutical Form of Losartan
05/14/2009US20090123535 Oral Controlled Release Formulation for Sedatives and Hypnotic Agents
05/14/2009US20090123534 comprising progesterone, soy bean lecithin, and olive oil, wherein at least about 80% of the particles of progesterone are characterized by a particle size of between 1 and 15 mu m; for treating a physiological condition linked to insufficiency of progesterone secretion
05/14/2009US20090123533 Compositions and methods for cancer diagnosis and therapy
05/14/2009US20090123532 Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite
05/14/2009US20090123530 Liposome Drug Delivery
05/14/2009US20090123529 Nucleic acid immunological composition for human metapneumovirus
05/14/2009US20090123528 Transdermal delivery of beneficial substances effected by a hostile biophysical environment
05/14/2009US20090123527 Method of inducing topical anesthesia and transdermal patch
05/14/2009US20090123526 Transdermally Absorbable Preparation
05/14/2009US20090123522 Medicament Delivery Device and a Method of Medicament Delivery
05/14/2009US20090123521 Medical devices having coatings for controlled therapeutic agent delivery
05/14/2009US20090123516 Drug delivery from implants using self-assembled monolayers-therapeutic sams
05/14/2009US20090123515 Polymer coatings containing drug powder of controlled morphology
05/14/2009US20090123513 Antimicrobial Biguanide Metal Complexes
05/14/2009US20090123512 Quorum Sensing Modulators
05/14/2009US20090123510 Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
05/14/2009US20090123504 Olive oil formulation for pain relief
05/14/2009US20090123501 Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines
05/14/2009US20090123493 Composition Comprising a Colloidal Synthetic Bioresorbable Vector and a Viral Vector
05/14/2009US20090123491 Novel method for preventing or treating M tuberculosis infection
05/14/2009US20090123480 Bivalent smac mimetics and the uses thereof
05/14/2009US20090123473 Human bnp immunospecific antibodies
05/14/2009US20090123472 Detection of mutations in a gene associated with resistance to viral infection, oas1
05/14/2009US20090123460 Immunostimulatory combinations
05/14/2009US20090123459 Compositions and method for the diagnosis, prevention and treatment of alzheimer's disease
05/14/2009US20090123456 determining whether an antibody is an agonist selective for nicotinic receptors, inhibits release of a proinflammatory cytokine from a mammalian cell, and if the antibody is reactive with nicotinic receptors; drug screening
05/14/2009US20090123447 Compositions and methods to inhibit rna viral reproduction
05/14/2009US20090123446 Use of IL-1 Antagonists to Treat Gout
05/14/2009US20090123425 Macrocyclic, pyridazinone-containing hepatitis c serine protease inhibitors
05/14/2009US20090123423 Hydroxyamic analogs as hepatitis c virus serine protease inhibitor